Akron Children's Logo
Skip to main content
Close Tools Menu Icon

Operator:

330-543-1000

Questions or Referrals:
ASK CHILDREN‘S

Close Phone Menu Icon
Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies

Zolmitriptan Nasal Spray for Acute Migraine Treatment in 6 to 11 year olds

Full IRB Study Title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension

IRB Study ID: IPX229-B16-01

For complete study details, please visit the study on clinicaltrials.gov.

Study Sponsor:

IMPAX Laboratories, Inc.

Who May Qualify:

Pediatric patients between 6 to 11 years old who have been diagnosed with migraines may be eligible to participate if:

  • They have migraines occurring at least 2 times per month with each episode lasting at least 3 hours.
  • They experience at least 16 headache-free days per month on average.

Who Does NOT Qualify:

Patients are not eligible to participate if:

  • They had not experienced satisfactory relief from migraine pain during prior treatment with 2 or more adequate courses of triptans
  • They have previously used any nasal spray (triptan or dihydroergotamine) for the acute treatment of migraine
  • They have a disease or medical condition which would exclude them from the study.

Lead Investigator

M. Cristina Victorio

M. Cristina Victorio, MD

Director, Headache Program; Pediatric Neurologist


NeuroDevelopmental Science CenterHeadache ClinicPediatric Neurology

More about this provider

Back to top of page

By using this site, you consent to our use of cookies. To learn more, read our privacy policy.